Moneycontrol News
Shares of Natco Pharma rose 3.6 percent intraday Monday as company has launched a generic version of Posaconazole Injection, 300 mg/16.7ml, under its brand POSANAT.
This is the first time an injection version of this drug available in India.
POSANAT will be available in 18 .0 mg/ml strength, a formulation for intravenous (IV) use. Posaconazole Injection is sold in the USA market by Merck under its brand name of NOXAFIL.
Posaconazole injection is an antifungal agent & used in patients who are at high risk of developing infections due to being severely immunocompromised, such as associated with stem cell transplant or from chemotherapy.
At 09:39 hrs Natco Pharma was quoting at Rs 798.65, up Rs 11.90, or 1.51 percent on the BSE.
Posted by Rakesh Patil
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
